Pharmacology of Polyphenols in Cardiac Remodeling: Potential Biological Mechanisms

Polyphenols in Human Health and Disease

Volumn 2, Issue , 2013, Pages 947-962

  Jiang, Fan ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac fibrosis; Cardiac hypertrophy; Cardiac remodeling; Heart failure; Pharmacology; Polyphenol

Indexed keywords

EID: 84902568621     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398456-2.00073-6     Document Type: Chapter

References (169)

1. Maisch B. Ventricular remodeling. Cardiology 1996, 87(Suppl. 1):2-10.
2. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35(3):569-582.
3. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122(25):2727-2735.
4. Takano H., Hasegawa H., Nagai T., Komuro I. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med 2003, 42(6):465-469.
5. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367(9507):356-367.
6. Brower G.L., Gardner J.D., Forman M.F., Murray D.B., Voloshenyuk T., Levick S.P., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30(4):604-610.
7. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007, 9(7):546-550.
8. Nicoletti A., Michel J.B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999, 41(3):532-543.
9. Bernardo B.C., Weeks K.L., Pretorius L., McMullen J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010, 128(1):191-227.
10. Stanton L.W., Garrard L.J., Damm D., Garrick B.L., Lam A., Kapoun A.M., et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res 2000, 86(9):939-945.
11. Fedak P.W., Verma S., Weisel R.D., Li R.K. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 2005, 14(1):1-11.
12. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100(9):999-1008.
13. Zamilpa R., Lindsey M.L. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 2010, 48(3):558-563.
14. Hao J., Kim C.H., Ha T.S., Ahn H.Y. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 2007, 8(2):121-129.
15. Sheng R., Gu Z.L., Xie M.L., Zhou W.X., Guo C.Y. EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med 2009, 75(2):113-120.
16. Li H.L., Huang Y., Zhang C.N., Liu G., Wei Y.S., Wang A.B., et al. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 2006, 40(10):1756-1775.
17. Chen D.D., Dong Y.G., Liu D., He J.G. Epigallocatechin-3-gallate attenuates cardiac hypertrophy partly via MAPKs signals in hypertensive rats. Clin Exp Pharmacol Physiol 2009, 36(9):926-932.
18. Sheng R., Gu Z.L., Xie M.L., Zhou W.X., Guo C.Y. EGCG inhibits cardiomyocyte apoptosis in pressure overload-induced cardiac hypertrophy and protects cardiomyocytes from oxidative stress in rats. Acta Pharmacol Sin 2007, 28(2):191-201.
19. Yamazaki K.G., Taub P.R., Barraza-Hidalgo M., Rivas M.M., Zambon A.C., Ceballos G., et al. Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J Am Coll Cardiol 2010, 55(25):2869-2876.
20. Suzuki J., Ogawa M., Maejima Y., Isobe K., Tanaka H., Sagesaka Y.M., et al. Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. J Mol Cell Cardiol 2007, 42(2):432-440.
21. Sutra T., Oiry C., Azay-Milhau J., Youl E., Magous R., Teissedre P.L., et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem 2008, 56(24):11683-11687.
22. Shen C.L., Samathanam C., Tatum O.L., Graham S., Tubb C., Cao J.J., et al. Green tea polyphenols avert chronic inflammation-induced myocardial fibrosis of female rats. Inflamm Res 2011, 60(7):665-672.
23. Mereles D., Buss S.J., Hardt S.E., Hunstein W., Katus H.A. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 2010, 99(8):483-490.
24. Han J.J., Hao J., Kim C.H., Hong J.S., Ahn H.Y., Lee Y.S. Quercetin prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Med Sci 2009, 71(6):737-743.
25. Jalili T., Carlstrom J., Kim S., Freeman D., Jin H., Wu T.C., et al. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol 2006, 47(4):531-541.
26. Galisteo M., Garcia-Saura M.F., Jimenez R., Villar I.C., Zarzuelo A., Vargas F., et al. Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats. Mol Cell Biochem 2004, 259(1-2):91-99.
27. Carlstrom J., Symons J.D., Wu T.C., Bruno R.S., Litwin S.E., Jalili T. A quercetin supplemented diet does not prevent cardiovascular complications in spontaneously hypertensive rats. J Nutr 2007, 137(3):628-633.
28. Duarte J., Perez-Palencia R., Vargas F., Ocete M.A., Perez-Vizcaino F., Zarzuelo A., et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 2001, 133(1):117-124.
29. Annapurna A., Reddy C.S., Akondi R.B., Rao S.R. Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats. J Pharm Pharmacol 2009, 61(10):1365-1374.
30. Qin T.C., Chen L., Yu L.X., Gu Z.L. Inhibitory effect of quercetin on cultured neonatal rat cardiomyocytes hypertrophy induced by angiotensin. Acta Pharmacol Sin 2001, 22(12):1103-1106.
31. Arumugam S., Thandavarayan R.A., Arozal W., Sari F.R., Giridharan V.V., Soetikno V., et al. Quercetin offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via endothelin-1/MAPK signalling. Free Radic Res 2012, 46(2):154-163.
32. Wojciechowski P., Juric D., Louis X.L., Thandapilly S.J., Yu L., Taylor C., et al. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J Nutr 2010, 140(5):962-968.
33. Biala A., Tauriainen E., Siltanen A., Shi J., Merasto S., Louhelainen M., et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press 2010, 19(3):196-205.
34. Inanaga K., Ichiki T., Matsuura H., Miyazaki R., Hashimoto T., Takeda K., et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res 2009, 32(6):466-471.
35. Qin F., Siwik D.A., Luptak I., Hou X., Wang L., Higuchi A., et al. The polyphenols resveratrol and S17834 prevent the structural and functional sequelae of diet-induced metabolic heart disease in mice. Circulation 2012, 125(14):1757-1764. S1-6.
36. Rimbaud S., Ruiz M., Piquereau J., Mateo P., Fortin D., Veksler V., et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 2011, 6(10):e26391.
37. Thandapilly S.J., Louis X.L., Yang T., Stringer D.M., Yu L., Zhang S., et al. Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. Eur J Pharmacol 2011, 668(1-2):217-224.
38. Lin J.F., Lin S.M., Chih C.L., Nien M.W., Su H.H., Hu B.R., et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 2008, 83(9-10):313-317.
39. Cheng T.H., Liu J.C., Lin H., Shih N.L., Chen Y.L., Huang M.T., et al. Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(2):239-244.
40. Olson E.R., Naugle J.E., Zhang X., Bomser J.A., Meszaros J.G. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 2005, 288(3):H1131-1138.
41. Wang S., Wang X., Yan J., Xie X., Fan F., Zhou X., et al. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur J Pharmacol 2007, 567(1-2):26-35.
42. Palfi A., Bartha E., Copf L., Mark L., Gallyas F., Veres B., et al. Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C alpha/beta II. J Nutr Biochem 2009, 20(6):418-425.
43. Bernatova I., Pechanova O., Babal P., Kysela S., Stvrtina S., Andriantsitohaina R. Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol Heart Circ Physiol 2002, 282(3):942-948.
44. Kong E.K., Yu S., Sanderson J.E., Chen K.B., Huang Y., Yu C.M. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol 2011, 658(2-3):175-181.
45. Shu C., Chen C., Zhang D.P., Guo H., Zhou H., Zong J., et al. Gastrodin protects against cardiac hypertrophy and fibrosis. Mol Cell Biochem 2012, 359(1-2):9-16.
46. Yan L., Huang H., Tang Q.Z., Zhu L.H., Wang L., Liu C., et al. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem 2010, 109(6):1158-1171.
47. Wang M., Zhang W.B., Zhu J.H., Fu G.S., Zhou B.Q. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin 2009, 30(8):1081-1091.
48. 2+-mediated calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 2010, 381(2):137-145.
49. Song Y.H., Cai H., Gu N., Qian C.F., Cao S.P., Zhao Z.M. Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. J Pharm Pharmacol 2011, 63(4):541-549.
50. Zibadi S., Yu Q., Rohdewald P.J., Larson D.F., Watson R.R. Impact of Pycnogenol on cardiac extracellular matrix remodeling induced by L-NAME administration to old mice. Cardiovasc Toxicol 2007, 7(1):10-18.
51. Morimoto T., Sunagawa Y., Kawamura T., Takaya T., Wada H., Nagasawa A., et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008, 118(3):868-878.
52. Oka T., Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 2008, 72(Suppl. A):A13-16.
53. Mishra S., Ling H., Grimm M., Zhang T., Bers D.M., Brown J.H. Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling. J Cardiovasc Pharmacol 2010, 56(6):598-603.
54. Kennedy M.B. Calcium/calmodulin-dependent protein kinase II. Handbook of Cell Signaling 2010, Academic Press, 565-568. 2nd ed. A. BR., E.A. Dennis (Eds.).
55. Xu Y., Lin D., Li S., Li G., Shyamala S.G., Barish P.A., et al. Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress. Neuropharmacology 2009, 57(4):463-471.
56. Fiedler B., Wollert K.C. Targeting calcineurin and associated pathways in cardiac hypertrophy and failure. Expert Opin Ther Targets 2005, 9(5):963-973.
57. Wang H., Zhou C.L., Lei H., Wei Q. Inhibition of calcineurin by quercetin in vitro and in Jurkat cells. J Biochem 2010, 147(2):185-190.
58. Wang H., Zhou C.L., Lei H., Zhang S.D., Zheng J., Wei Q. Kaempferol: a new immunosuppressant of calcineurin. IUBMB Life 2008, 60(8):549-554.
59. Rose B.A., Force T., Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010, 90(4):1507-1546.
60. Nicol R.L., Frey N., Pearson G., Cobb M., Richardson J., Olson E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001, 20(11):2757-2767.
61. Kimura T.E., Jin J., Zi M., Prehar S., Liu W., Oceandy D., et al. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 2010, 106(5):961-970.
62. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81(2):807-869.
63. Li Z., Li J., Mo B., Hu C., Liu H., Qi H., et al. Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 2008, 22(7):1749-1753.
64. Thorburn J., Thorburn A. The tyrosine kinase inhibitor, genistein, prevents alpha-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway. Biochem Biophys Res Commun 1994, 202(3):1586-1591.
65. Li J., Xie Z.Z., Tang Y.B. Genistein prevents myocardial hypertrophy in 2-kidney 1-clip renal hypertensive rats by restoring eNOS pathway. Pharmacology 2010, 86(4):240-248.
66. Song Y.A., Park Y.L., Yoon S.H., Kim K.Y., Cho S.B., Lee W.S., et al. Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-kappaB and JNK activation in intestinal epithelial cells. Inflamm Res 2011, 60(5):493-500.
67. Bhattacharya U., Halder B., Mukhopadhyay S., Giri A.K. Role of oxidation-triggered activation of JNK and p38 MAPK in black tea polyphenols induced apoptotic death of A375 cells. Cancer Sci 2009, 100(10):1971-1978.
68. Jia L., Li Y., Xiao C., Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci 2012, 17:221-231.
69. Khaper N., Bryan S., Dhingra S., Singal R., Bajaj A., Pathak C.M., et al. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 2010, 13(7):1033-1049.
70. Wrigley B.J., Lip G.Y., Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011, 13(11):1161-1171.
71. Jiang B., Liao R. The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res 2010, 3(4):410-416.
72. Frantz S., Bauersachs J., Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009, 81(3):474-481.
73. Jiang F., Dusting G.J. Natural phenolic compounds as cardiovascular therapeutics: potential role of their antiinflammatory effects. Curr Vasc Pharmacol 2003, 1(2):135-156.
74. Aneja R., Hake P.W., Burroughs T.J., Denenberg A.G., Wong H.R., Zingarelli B. Epigallocatechin a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 2004, 10(1-6):55-62.
75. Kim H.J., Tsoy I., Park J.M., Chung J.I., Shin S.C., Chang K.C. Anthocyanins from soybean seed coat inhibit the expression of TNF-alpha-induced genes associated with ischemia/reperfusion in endothelial cell by NF-kappaB-dependent pathway and reduce rat myocardial damages incurred by ischemia and reperfusion in vivo. FEBS Lett 2006, 580(5):1391-1397.
76. Jiang F., Guo N., Dusting G.J. 3',4'-Dihydroxyflavonol down-regulates monocyte chemoattractant protein-1 in smooth muscle: role of focal adhesion kinase and PDGF receptor signalling. Br J Pharmacol 2009, 157(4):597-606.
77. Kawano S., Kubota T., Monden Y., Kawamura N., Tsutsui H., Takeshita A., et al. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 2005, 67(4):689-698.
78. Hamid T., Guo S.Z., Kingery J.R., Xiang X., Dawn B., Prabhu S.D. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011, 89(1):129-138.
79. Yang F., Oz H.S., Barve S., de Villiers W.J., McClain C.J., Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001, 60(3):528-533.
80. Kunnumakkara A.B., Nair A.S., Ahn K.S., Pandey M.K., Yi Z., Liu M., et al. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood 2007, 109(12):5112-5121.
81. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999, 163(6):3474-3483.
82. Bharti A.C., Donato N., Singh S., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101(3):1053-1062.
83. Yeh C.H., Lin Y.M., Wu Y.C., Lin P.J. Inhibition of NF-kappa B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression. J Cardiovasc Pharmacol 2005, 45(4):301-309.
84. Mito S., Watanabe K., Harima M., Thandavarayan R.A., Veeraveedu P.T., Sukumaran V., et al. Curcumin ameliorates cardiac inflammation in rats with autoimmune myocarditis. Biol Pharm Bull 2011, 34(7):974-979.
85. Tsutsui H., Kinugawa S., Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011, 301(6):H2181-2190.
86. Chen Y.L., Liu J.C., Loh S.H., Chen C.H., Hong C.Y., Chen J.J., et al. Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 2008, 593(1-3):24-29.
87. Lijnen P., Papparella I., Petrov V., Semplicini A., Fagard R. Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species. J Hypertens 2006, 24(4):757-766.
88. Jiang F., Chang C.W., Dusting G.J. Cytoprotection by natural and synthetic polyphenols in the heart: novel mechanisms and perspectives. Curr Pharm Des 2010, 16(37):4103-4112.
89. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M.D., Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010, 107(35):15565-15570.
90. Bendall J.K., Cave A.C., Heymes C., Gall N., Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002, 105(3):293-296.
91. Cayatte A.J., Rupin A., Oliver-Krasinski J., Maitland K., Sansilvestri-Morel P., Boussard M.F., et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 2001, 21(10):1577-1584.
92. Jaulmes A., Sansilvestri-Morel P., Rolland-Valognes G., Bernhardt F., Gaertner R., Lockhart B.P., et al. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb Res 2009, 124(4):439-446.
93. Jiang F., Guo N., Dusting G.J. Modulation of nicotinamide adenine dinucleotide phosphate oxidase expression and function by 3',4'-dihydroxyflavonol in phagocytic and vascular cells. J Pharmacol Exp Ther 2008, 324(1):261-269.
94. Sanchez M., Galisteo M., Vera R., Villar I.C., Zarzuelo A., Tamargo J., et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 2006, 24(1):75-84.
95. Jiang F., Zhang Y., Dusting G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 2011, 63(1):218-242.
96. Zhang M., Perino A., Ghigo A., Hirsch E., Shah A. NADPH oxidases in heart failure: poachers or gamekeepers?. Antioxid Redox Signal 2012, 18(9):1024-1041.
97. Brown R.D., Ambler S.K., Mitchell M.D., Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657-687.
98. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105(12):1164-1176.
99. Pan Z., Zhao W., Zhang X., Wang B., Wang J., Sun X., et al. Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFbeta1 expression and activation of p38-MAPK and ERK1/2. Br J Pharmacol 2011, 162(3):688-700.
100. Nakamura T., Matsushima M., Hayashi Y., Shibasaki M., Imaizumi K., Hashimoto N., et al. Attenuation of transforming growth factor-beta-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am J Respir Cell Mol Biol 2011, 44(5):614-620.
101. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89(2):265-272.
102. Park S.J., Jeong J.M., Jeong H.S., Park J.S., Kim N.H. Effects of epigallocatechin-3-gallate on the expression of TGF-beta1, PKC alpha/betaII, and NF-kappaB in high-glucose-stimulated glomerular epithelial cells. Chonnam Med J 2011, 47(2):116-121.
103. Qi M.Y., Kai C., Liu H.R., Su Y.H., Yu S.Q. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor beta1 and type IV collagen expression in rats. J Ethnopharmacol 2011, 138(3):731-736.
104. Dandawate S., Williams L., Joshee N., Rimando A.M., Mittal S., Thakur A., et al. Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-beta1 activity. Cancer Immunol Immunother 2012, 61(5):701-711.
105. Yang Y., Xu Y., Xia T., Chen F., Zhang C., Liang W., et al. A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-beta ligand-receptor binding. Chem Commun (Camb) 2011, 47(19):5440-5442.
106. Liu X., Wang W., Hu H., Tang N., Zhang C., Liang W., et al. Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm Res 2006, 23(1):82-89.
107. Phan T.T., Lim I.J., Chan S.Y., Tan E.K., Lee S.T., Longaker M.T. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma 2004, 57(5):1032-1037.
108. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 2001, 89(3):201-210.
109. Demeule M., Brossard M., Page M., Gingras D., Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 2000, 1478(1):51-60.
110. Nakamuta M., Higashi N., Kohjima M., Fukushima M., Ohta S., Kotoh K., et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int J Mol Med 2005, 16(4):677-681.
111. Oku N., Matsukawa M., Yamakawa S., Asai T., Yahara S., Hashimoto F., et al. Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol Pharm Bull 2003, 26(9):1235-1238.
112. El Bedoui J., Oak M.H., Anglard P., Schini-Kerth V.B. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovasc Res 2005, 67(2):317-325.
113. Grimm T., Schafer A., Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 2004, 36(6):811-822.
114. Wollert K.C., Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002, 7(4):317-325.
115. Ruiz-Hurtado G., Fernandez-Velasco M., Mourelle M., Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007, 50(6):1049-1056.
116. Ruetten H., Dimmeler S., Gehring D., Ihling C., Zeiher A.M. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005, 66(3):444-453.
117. Calvieri C., Rubattu S., Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med (Berl) 2011, 90(1):5-13.
118. Kishimoto I., Tokudome T., Horio T., Garbers D.L., Nakao K., Kangawa K. Natriuretic peptide signaling via guanylyl cyclase (GC)-A: an endogenous protective mechanism of the heart. Curr Cardiol Rev 2009, 5(1):45-51.
119. Hammond J., Balligand J.L. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol 2012, 52(2):330-340.
120. Suga S., Nakao K., Itoh H., Komatsu Y., Ogawa Y., Hama N., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest 1992, 90(3):1145-1149.
121. Izumiya Y., Araki S., Usuku H., Rokutanda T., Hanatani S., Ogawa H. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med 2012, 2012:246058.
122. Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin 2003, 24(7):625-630.
123. Francois H., Athirakul K., Howell D., Dash R., Mao L., Kim H.S., et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2005, 2(3):201-207.
124. Hara A., Yuhki K., Fujino T., Yamada T., Takayama K., Kuriyama S., et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor. Circulation 2005, 112(1):84-92.
125. Chan E.C., Dusting G.J., Guo N., Peshavariya H.M., Taylor C.J., Dilley R., et al. Prostacyclin receptor suppresses cardiac fibrosis: role of CREB phosphorylation. J Mol Cell Cardiol 2010, 49(2):176-185.
126. Stoclet J.C., Chataigneau T., Ndiaye M., Oak M.H., El Bedoui J., Chataigneau M., et al. Vascular protection by dietary polyphenols. Eur J Pharmacol 2004, 500(1-3):299-313.
127. Hermenegildo C., Oviedo P.J., Garcia-Perez M.A., Tarin J.J., Cano A. Effects of phytoestrogens genistein and daidzein on prostacyclin production by human endothelial cells. J Pharmacol Exp Ther 2005, 315(2):722-728.
128. Uydes-Dogan B.S., Takir S., Ozdemir O., Kolak U., Topcu G., Ulubelen A. The comparison of the relaxant effects of two methoxylated flavones in rat aortic rings. Vascul Pharmacol 2005, 43(4):220-226.
129. Paoletti T., Fallarini S., Gugliesi F., Minassi A., Appendino G., Lombardi G. Anti-inflammatory and vascularprotective properties of 8-prenylapigenin. Eur J Pharmacol 2009, 620(1-3):120-130.
130. Mizugaki M., Ishizawa F., Yamazaki T., Hishinuma T. Epigallocatechin gallate increase the prostacyclin production of bovine aortic endothelial cells. Prostaglandins Other Lipid Mediat 2000, 62(2):157-164.
131. Ferdous A., Battiprolu P.K., Ni Y.G., Rothermel B.A., Hill J.A. FoxO autophagy, and cardiac remodeling. J Cardiovasc Transl Res 2010, 3(4):355-364.
132. Kanamori H., Takemura G., Goto K., Maruyama R., Tsujimoto A., Ogino A., et al. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc Res 2011, 91(2):330-339.
133. Gurusamy N., Das D.K Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal 2009, 11(8):1975-1988.
134. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007, 13(5):619-624.
135. Matsui Y., Takagi H., Qu X., Abdellatif M., Sakoda H., Asano T., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007, 100(6):914-922.
136. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007, 117(7):1782-1793.
137. Nishida K., Kyoi S., Yamaguchi O., Sadoshima J., Otsu K. The role of autophagy in the heart. Cell Death Differ 2009, 16(1):31-38.
138. Han J., Pan X.Y., Xu Y., Xiao Y., An Y., Tie L., et al. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 2012, 8(5):812-825.
139. Li W., Zhu S., Li J., Assa A., Jundoria A., Xu J., et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 2011, 81(9):1152-1163.
140. Lv X.C., Zhou H.Y. Resveratrol protects H9c2 embryonic rat heart derived cells from oxidative stress by inducing autophagy: role of p38 mitogen-activated protein kinase. Can J Physiol Pharmacol 2012, 90(5):655-662.
141. Puissant A., Robert G., Fenouille N., Luciano F., Cassuto J.P., Raynaud S., et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010, 70(3):1042-1052.
142. Wu Y., Li X., Zhu J.X., Xie W., Le W., Fan Z., et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 2011, 19(3):163-174.
143. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010, 285(12):9100-9113.
144. Morselli E., Maiuri M.C., Markaki M., Megalou E., Pasparaki A., Palikaras K., et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis 2010, 1:e10.
145. Xu X., Chen K., Kobayashi S., Timm D., Liang Q. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 2012, 341(1):183-195.
146. Wang K., Liu R., Li J., Mao J., Lei Y., Wu J., et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1alpha-mediated signaling. Autophagy 2011, 7(9):966-978.
147. Psahoulia F.H., Moumtzi S., Roberts M.L., Sasazuki T., Shirasawa S., Pintzas A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 2007, 28(5):1021-1031.
148. Filomeni G., Graziani I., De Zio D., Dini L., Centonze D., Rotilio G., et al. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease. Neurobiol Aging 2012, 33(4):767-785.
149. Chung S., Yao H., Caito S., Hwang J.W., Arunachalam G., Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010, 501(1):79-90.
150. Botden I.P., Oeseburg H., Durik M., Leijten F.P., Van Vark-Van Der Zee L.C., Musterd-Bhaggoe U.M., et al. Red wine extract protects against oxidative-stress-induced endothelial senescence. Clin Sci (Lond) 2012, 123(8):499-507.
151. Wang Q., Liu M., Liu W.W., Hao W.B., Tashiro S., Onodera S., et al. In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic beta-cell. J Asian Nat Prod Res 2012, 14(5):413-423.
152. Yokozawa T., Lee Y.A., Zhao Q., Matsumoto K., Cho E.J. Persimmon oligomeric proanthocyanidins extend life span of senescence-accelerated mice. J Med Food 2009, 12(6):1199-1205.
153. Rasbach K.A., Schnellmann R.G. Isoflavones promote mitochondrial biogenesis. J Pharmacol Exp Ther 2008, 325(2):536-543.
154. Wen M., Wu J., Luo H., Zhang H. Galangin induces autophagy through upregulation of p53 in HepG2 cells. Pharmacology 2012, 89(5-6):247-255.
155. Lorenzen J.M., Martino F., Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol 2012, 107(2):245.
156. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004, 279(49):51163-51171.
157. Xiao X., Shi D., Liu L., Wang J., Xie X., Kang T., et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One 2011, 6(8):e22934.
158. Seong A.R., Yoo J.Y., Choi K., Lee M.H., Lee Y.H., Lee J., et al. Delphinidin, a specific inhibitor of histone acetyltransferase, suppresses inflammatory signaling via prevention of NF-kappaB acetylation in fibroblast-like synoviocyte MH7A cells. Biochem Biophys Res Commun 2011, 410(3):581-586.
159. Choi K.C., Park S., Lim B.J., Seong A.R., Lee Y.H., Shiota M., et al. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor. Biochem J 2011, 433(1):235-244.
160. Choi K.C., Jung M.G., Lee Y.H., Yoon J.C., Kwon S.H., Kang H.B., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res 2009, 69(2):583-592.
161. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13(3):324-331.
162. Bontempo P., Mita L., Miceli M., Doto A., Nebbioso A., De Bellis F., et al. Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. Int J Biochem Cell Biol 2007, 39(10):1902-1914.
163. Pal-Bhadra M., Ramaiah M.J., Reddy T.L., Krishnan A., Pushpavalli S.N., Babu K.S., et al. Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 2012, 12:180.
164. Son I.H., Chung I.M., Lee S.I., Yang H.D., Moon H.I. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett 2007, 17(17):4753-4755.
165. Attoub S., Hassan A.H., Vanhoecke B., Iratni R., Takahashi T., Gaben A.M., et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 2011, 651(1-3):18-25.
166. Waldecker M., Kautenburger T., Daumann H., Busch C., Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 2008, 19(9):587-593.
167. Scalbert A., Manach C., Morand C., Remesy C., Jimenez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005, 45(4):287-306.
168. Uyama H. Artificial polymeric flavonoids: synthesis and applications. Macromol Biosci 2007, 7(4):410-422.
169. Lebeau J., Neviere R., Cotelle N. Beneficial effects of different flavonoids, on functional recovery after ischemia and reperfusion in isolated rat heart. Bioorg Med Chem Lett 2001, 11(1):23-27.